Difference between revisions of "Pancreatic cancer - historical"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "%3C" to "<") |
Warner-admin (talk | contribs) m (Text replacement - "'''contains dosing details in abstract'''" to "'''dosing details in abstract have been reviewed by our editors'''") |
||
(20 intermediate revisions by 2 users not shown) | |||
Line 1: | Line 1: | ||
− | The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only | + | The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. Is there a regimen missing from this list? See the [[Pancreatic_cancer|main pancreatic cancer page]] for current regimens. |
− | |||
{| class="wikitable" style="float:right; margin-right: 5px;" | {| class="wikitable" style="float:right; margin-right: 5px;" | ||
|- | |- | ||
Line 6: | Line 5: | ||
<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div> | <div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div> | ||
|} | |} | ||
− | |||
{{TOC limit|limit=3}} | {{TOC limit|limit=3}} | ||
− | |||
=Induction therapy for locally advanced disease, unresectable= | =Induction therapy for locally advanced disease, unresectable= | ||
==FLEC {{#subobject:a6c123|Regimen=1}}== | ==FLEC {{#subobject:a6c123|Regimen=1}}== | ||
− | |||
FLEC: '''<u>F</u>'''luorouracil, '''<u>L</u>'''eucovorin (Folinic acid), '''<u>E</u>'''pirubicin, '''<u>C</u>'''arboplatin | FLEC: '''<u>F</u>'''luorouracil, '''<u>L</u>'''eucovorin (Folinic acid), '''<u>E</u>'''pirubicin, '''<u>C</u>'''arboplatin | ||
+ | <div class="toccolours" style="background-color:#ee6b6e"> | ||
===Regimen {{#subobject:ac72e0|Variant=1}}=== | ===Regimen {{#subobject:ac72e0|Variant=1}}=== | ||
{| class="wikitable sortable" style="width: 100%; text-align:center;" | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
! style="width: 20%" |Study | ! style="width: 20%" |Study | ||
− | ! style="width: 20%" | | + | ! style="width: 20%" |Dates of enrollment |
! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] | ||
! style="width: 20%" |Comparator | ! style="width: 20%" |Comparator | ||
! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
|- | |- | ||
− | |[https:// | + | |[https://doi.org/10.1179/joc.2004.16.6.589 Cantore et al. 2004] |
|1997-2001 | |1997-2001 | ||
| style="background-color:#1a9851" |Phase 3 (E-esc) | | style="background-color:#1a9851" |Phase 3 (E-esc) | ||
|[[Pancreatic_cancer#Gemcitabine_monotherapy_2|Gemcitabine]] | |[[Pancreatic_cancer#Gemcitabine_monotherapy_2|Gemcitabine]] | ||
− | | style="background-color:#91cf60" |Seems to have superior OS | + | | style="background-color:#91cf60" |Seems to have superior OS (primary endpoint) |
|- | |- | ||
|} | |} | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | + | *[[Fluorouracil (5-FU)]] 1000 mg/m<sup>2</sup> IA bolus once on day 1 | |
− | *[[Fluorouracil (5-FU)]] | + | *[[Leucovorin (Folinic acid)]] 100 mg/m<sup>2</sup> IA bolus once on day 1 |
− | *[[Folinic acid | + | *[[Epirubicin (Ellence)]] 60 mg/m<sup>2</sup> IA bolus once on day 1 |
− | *[[Epirubicin (Ellence)]] | + | *[[Carboplatin (Paraplatin)]] 300 mg/m<sup>2</sup> IA bolus once on day 1 |
− | *[[Carboplatin (Paraplatin)]] | + | '''21-day cycle for 3 cycles''' |
− | + | </div></div> | |
===References=== | ===References=== | ||
− | + | #Cantore M, Fiorentini G, Luppi G, Rosati G, Caudana R, Piazza E, Comella G, Ceravolo C, Miserocchi L, Mambrini A, Del Freo A, Zamagni D, Rabbi C, Marangolo M. Gemcitabine versus FLEC regimen given intra-arterially to patients with unresectable pancreatic cancer: a prospective, randomized phase III trial of the Italian Society for Integrated Locoregional Therapy in Oncology. J Chemother. 2004 Dec;16(6):589-94. [https://doi.org/10.1179/joc.2004.16.6.589 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/15700852/ PubMed] | |
− | #Cantore M, Fiorentini G, Luppi G, Rosati G, Caudana R, Piazza E, Comella G, Ceravolo C, Miserocchi L, Mambrini A, Del Freo A, Zamagni D, Rabbi C, Marangolo M. Gemcitabine versus FLEC regimen given intra-arterially to patients with unresectable pancreatic cancer: a prospective, randomized phase III trial of the Italian Society for Integrated Locoregional Therapy in Oncology. J Chemother. 2004 Dec;16(6):589-94. [https:// | ||
=Metastatic disease, first-line= | =Metastatic disease, first-line= | ||
==PEFG {{#subobject:f0e123|Regimen=1}}== | ==PEFG {{#subobject:f0e123|Regimen=1}}== | ||
− | |||
PEFG: '''<u>P</u>'''latinol (Cisplatin), '''<u>E</u>'''pirubicin, '''<u>F</u>'''luorouracil, '''<u>G</u>'''emcitabine | PEFG: '''<u>P</u>'''latinol (Cisplatin), '''<u>E</u>'''pirubicin, '''<u>F</u>'''luorouracil, '''<u>G</u>'''emcitabine | ||
+ | <div class="toccolours" style="background-color:#ee6b6e"> | ||
===Regimen {{#subobject:5d6ee0|Variant=1}}=== | ===Regimen {{#subobject:5d6ee0|Variant=1}}=== | ||
{| class="wikitable sortable" style="width: 100%; text-align:center;" | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
!style="width: 20%"|Study | !style="width: 20%"|Study | ||
− | !style="width: 20%"| | + | !style="width: 20%"|Dates of enrollment |
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
!style="width: 20%"|Comparator | !style="width: 20%"|Comparator | ||
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | !style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
|- | |- | ||
− | |[https:// | + | |[https://doi.org/10.1016/S1470-2045(05)70175-3 Reni et al. 2005] |
|2000-2003 | |2000-2003 | ||
| style="background-color:#1a9851" |Phase 3 (E-esc) | | style="background-color:#1a9851" |Phase 3 (E-esc) | ||
− | |[[Pancreatic_cancer# | + | |[[Pancreatic_cancer#Gemcitabine_monotherapy_5|Gemcitabine]] |
− | | style="background-color:# | + | | style="background-color:#1a9850" |Superior PFS4 (primary endpoint)<br>PFS4: 60% vs 28%<br>(HR 0.46, 95% CI 0.26-0.79) |
|- | |- | ||
|} | |} | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | |||
*[[Cisplatin (Platinol)]] 40 mg/m<sup>2</sup> IV once on day 1 | *[[Cisplatin (Platinol)]] 40 mg/m<sup>2</sup> IV once on day 1 | ||
*[[Epirubicin (Ellence)]] 40 mg/m<sup>2</sup> IV once on day 1 | *[[Epirubicin (Ellence)]] 40 mg/m<sup>2</sup> IV once on day 1 | ||
*[[Fluorouracil (5-FU)]] 200 mg/m<sup>2</sup>/day IV continuous infusion over 28 days, started on day 1 (total dose per cycle: 5600 mg/m<sup>2</sup>) | *[[Fluorouracil (5-FU)]] 200 mg/m<sup>2</sup>/day IV continuous infusion over 28 days, started on day 1 (total dose per cycle: 5600 mg/m<sup>2</sup>) | ||
*[[Gemcitabine (Gemzar)]] 600 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1 & 8 | *[[Gemcitabine (Gemzar)]] 600 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1 & 8 | ||
− | |||
'''28-day cycles''' | '''28-day cycles''' | ||
− | + | </div></div> | |
===References=== | ===References=== | ||
− | + | #Reni M, Cordio S, Milandri C, Passoni P, Bonetto E, Oliani C, Luppi G, Nicoletti R, Galli L, Bordonaro R, Passardi A, Zerbi A, Balzano G, Aldrighetti L, Staudacher C, Villa E, Di Carlo V. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. Lancet Oncol. 2005 Jun;6(6):369-76. [https://doi.org/10.1016/S1470-2045(05)70175-3 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/15925814/ PubMed] | |
− | #Reni M, Cordio S, Milandri C, Passoni P, Bonetto E, Oliani C, Luppi G, Nicoletti R, Galli L, Bordonaro R, Passardi A, Zerbi A, Balzano G, Aldrighetti L, Staudacher C, Villa E, Di Carlo V. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. Lancet Oncol. 2005 Jun;6(6):369-76. [https:// | ||
=Metastatic disease, all lines of therapy= | =Metastatic disease, all lines of therapy= | ||
==SMF {{#subobject:f7dcb5|Regimen=1}}== | ==SMF {{#subobject:f7dcb5|Regimen=1}}== | ||
− | |||
SMF: '''<u>S</u>'''treptozotocin, '''<u>M</u>'''itomycin, 5-'''<u>F</u>'''luorouracil | SMF: '''<u>S</u>'''treptozotocin, '''<u>M</u>'''itomycin, 5-'''<u>F</u>'''luorouracil | ||
+ | <div class="toccolours" style="background-color:#ee6b6e"> | ||
===Regimen {{#subobject:251b74|Variant=1}}=== | ===Regimen {{#subobject:251b74|Variant=1}}=== | ||
{| class="wikitable sortable" style="width: 100%; text-align:center;" | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
!style="width: 20%"|Study | !style="width: 20%"|Study | ||
− | !style="width: 20%"| | + | !style="width: 20%"|Dates of enrollment |
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
!style="width: 20%"|Comparator | !style="width: 20%"|Comparator | ||
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | !style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
|- | |- | ||
− | |[https://doi.org/10.1002/1097-0142(19910901)68:5 | + | |[https://doi.org/10.1002/1097-0142(19910901)68:5%3C965::aid-cncr2820680509%3E3.0.co;2-2 Kelsen et al. 1991] |
|1987-1989 | |1987-1989 | ||
| style="background-color:#1a9851" |Phase 3 (C) | | style="background-color:#1a9851" |Phase 3 (C) | ||
− | |[[# | + | |[[#CAC_999|CAC]] |
| style="background-color:#1a9850" |Superior OS | | style="background-color:#1a9850" |Superior OS | ||
|- | |- | ||
|} | |} | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[Streptozocin (Zanosar)]] | + | *[[Streptozocin (Zanosar)]] 1000 mg/m<sup>2</sup> IV once per day on days 1, 8, 29, 36 |
− | *[[Mitomycin (Mutamycin)]] | + | *[[Mitomycin (Mutamycin)]] 10 mg/m<sup>2</sup> IV once on day 1 |
− | *[[Fluorouracil (5-FU)]] | + | *[[Fluorouracil (5-FU)]] 600 mg/m<sup>2</sup> IV once per day on days 1, 8, 29, 36 |
− | + | '''8-week cycles''' | |
+ | </div></div> | ||
===References=== | ===References=== | ||
− | #Kelsen D, Hudis C, Niedzwiecki D, Dougherty J, Casper E, Botet J, Vinciguerra V, Rosenbluth R. A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma. Cancer. 1991 Sep 1;68(5):965-9. [https://doi.org/10.1002/1097-0142(19910901)68:5 | + | #Kelsen D, Hudis C, Niedzwiecki D, Dougherty J, Casper E, Botet J, Vinciguerra V, Rosenbluth R. A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma. Cancer. 1991 Sep 1;68(5):965-9. [https://doi.org/10.1002/1097-0142(19910901)68:5%3C965::aid-cncr2820680509%3E3.0.co;2-2 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/1833042/ PubMed] |
− | |||
[[Category:Pancreatic cancer regimens]] | [[Category:Pancreatic cancer regimens]] | ||
[[Category:Disease-specific pages]] | [[Category:Disease-specific pages]] | ||
[[Category:Gastrointestinal cancers]] | [[Category:Gastrointestinal cancers]] | ||
[[Category:Historical regimens]] | [[Category:Historical regimens]] |
Latest revision as of 23:34, 15 July 2024
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. Is there a regimen missing from this list? See the main pancreatic cancer page for current regimens.
3 regimens on this page
3 variants on this page
|
Induction therapy for locally advanced disease, unresectable
FLEC
FLEC: Fluorouracil, Leucovorin (Folinic acid), Epirubicin, Carboplatin
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Cantore et al. 2004 | 1997-2001 | Phase 3 (E-esc) | Gemcitabine | Seems to have superior OS (primary endpoint) |
Chemotherapy
- Fluorouracil (5-FU) 1000 mg/m2 IA bolus once on day 1
- Leucovorin (Folinic acid) 100 mg/m2 IA bolus once on day 1
- Epirubicin (Ellence) 60 mg/m2 IA bolus once on day 1
- Carboplatin (Paraplatin) 300 mg/m2 IA bolus once on day 1
21-day cycle for 3 cycles
References
- Cantore M, Fiorentini G, Luppi G, Rosati G, Caudana R, Piazza E, Comella G, Ceravolo C, Miserocchi L, Mambrini A, Del Freo A, Zamagni D, Rabbi C, Marangolo M. Gemcitabine versus FLEC regimen given intra-arterially to patients with unresectable pancreatic cancer: a prospective, randomized phase III trial of the Italian Society for Integrated Locoregional Therapy in Oncology. J Chemother. 2004 Dec;16(6):589-94. link to original article dosing details in abstract have been reviewed by our editors PubMed
Metastatic disease, first-line
PEFG
PEFG: Platinol (Cisplatin), Epirubicin, Fluorouracil, Gemcitabine
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Reni et al. 2005 | 2000-2003 | Phase 3 (E-esc) | Gemcitabine | Superior PFS4 (primary endpoint) PFS4: 60% vs 28% (HR 0.46, 95% CI 0.26-0.79) |
Chemotherapy
- Cisplatin (Platinol) 40 mg/m2 IV once on day 1
- Epirubicin (Ellence) 40 mg/m2 IV once on day 1
- Fluorouracil (5-FU) 200 mg/m2/day IV continuous infusion over 28 days, started on day 1 (total dose per cycle: 5600 mg/m2)
- Gemcitabine (Gemzar) 600 mg/m2 IV over 60 minutes once per day on days 1 & 8
28-day cycles
References
- Reni M, Cordio S, Milandri C, Passoni P, Bonetto E, Oliani C, Luppi G, Nicoletti R, Galli L, Bordonaro R, Passardi A, Zerbi A, Balzano G, Aldrighetti L, Staudacher C, Villa E, Di Carlo V. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. Lancet Oncol. 2005 Jun;6(6):369-76. link to original article dosing details in abstract have been reviewed by our editors PubMed
Metastatic disease, all lines of therapy
SMF
SMF: Streptozotocin, Mitomycin, 5-Fluorouracil
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Kelsen et al. 1991 | 1987-1989 | Phase 3 (C) | CAC | Superior OS |
Chemotherapy
- Streptozocin (Zanosar) 1000 mg/m2 IV once per day on days 1, 8, 29, 36
- Mitomycin (Mutamycin) 10 mg/m2 IV once on day 1
- Fluorouracil (5-FU) 600 mg/m2 IV once per day on days 1, 8, 29, 36
8-week cycles
References
- Kelsen D, Hudis C, Niedzwiecki D, Dougherty J, Casper E, Botet J, Vinciguerra V, Rosenbluth R. A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma. Cancer. 1991 Sep 1;68(5):965-9. link to original article dosing details in manuscript have been reviewed by our editors PubMed